Revvity, Inc. (RVTY) Stock Analysis

Revvity (RVTY) is a Waltham, Massachusetts-based diagnostics and life sciences tools company operating in the healthcare sector. They sell laboratory instruments, specialized testing reagents, imaging systems, and software like ChemDraw to pharmaceutical companies, commercial diagnostic labs, and research universities. Their diagnostics unit specializes in early screening tools for conditions such as Down syndrome, hypothyroidism, and infectious diseases, while their life sciences catalog provides gene sequencing and drug discovery platforms. Essentially, they supply the specialized hardware, consumables, and software that laboratories need to run clinical tests and develop new therapies.

Revvity operates as a specialized challenger in life sciences and a market leader in reproductive and newborn genetic screening. Their primary moat comes from locking clinical labs into recurring revenue through proprietary assays and specialized brands like BioLegend and EUROIMMUN. Scale players like Thermo Fisher Scientific and Agilent Technologies have broader catalog reach and larger distribution networks, which keeps pricing pressure high on general lab hardware. However, Revvity holds a distinct edge in immunodiagnostics and neonatal testing workflows where customer switching costs are steep.

The company underwent a major structural pivot in April 2023, shedding its legacy industrial units and rebranding from PerkinElmer, Inc., which was originally founded in 1937. Today, management is focused purely on life sciences and diagnostics, targeting long-term organic revenue growth of 6% to 8%. The transformation sharpens their business model around high-margin consumables and software subscriptions, which create a steady stream of recurring sales. Shedding lower-growth industrial operations created a much cleaner profile, but hitting that growth target while biotech funding stays tight is their main operational challenge.